Abstract: The present invention relates to aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives of the formula (I) or a physiologically tolerated salt thereof The invention relates to pharmaceutical compositions comprising such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, and the use of such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquin oline derivatives for therapeutic purposes. The aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives are GlyT1 inhibitors.

Abstract: The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) wherein R1, R2, R3, R4, R5, A, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Abstract: The present invention provides an apparatus for manufacturing semiconductor wafer comprising at least two manipulators, at least one set of chemical gas/liquid distribution unit and an air circulating and filtering unit. The air circulating and filtering unit is separated into three regions, including the front region, the middle region, and the side region, which are controlled by respective control electric motors to achieve uniform air flow and uniform pressure in the respective regions. The cleaning degree in the internal of the apparatus can be improved by the regional control of the air circulating and filtering unit; the wafer transport efficiency can be enhanced by the double-armed manipulators having multiple degrees of freedom; and the product yield per unit area can be increased by the chemical gas/liquid distribution unit providing stable and uniform gas/liquid flow and pressure.

Abstract: The present invention provides an apparatus for manufacturing semiconductor wafer comprising at least two manipulators, at least one set of chemical gas/liquid distribution unit and an air circulating and filtering unit. The air circulating and filtering unit is separated into three regions, including the front region, the middle region, and the side region, which are controlled by respective control electric motors to achieve uniform air flow and uniform pressure in the respective regions. The cleaning degree in the internal of the apparatus can be improved by the regional control of the air circulating and filtering unit; the wafer transport efficiency can be enhanced by the double-armed manipulators having multiple degrees of freedom; and the product yield per unit area can be increased by the chemical gas/liquid distribution unit providing stable and uniform gas/liquid flow and pressure.

Abstract: The present invention relates to efficient synthetic method of 1,3,5-tris (N-Phenylbenzimidazole) Benzene and pertains to the field of synthesis of organic light-emitting materials. The method and process of the patent are as following: 1,3,5-tris (N-Phenyl-N Phenylammonium) Benzamide is treated by shrinking agent but no high temperature required, and then high purity product can be reached after raw material dissolved. The reaction only takes a few minutes and through recrystallization the purity can be over 99%, and then the material with stable crystal phase reached after sublimation step. The method introduced by the present patent is easy to operate, and with high in yield and purity, which adapt industrial production and has important significance for the industrialization.

Abstract: The present invention relates to Aromatic ring substituted dianthracene compounds and pertains to the field of synthesis of organic light-emitting materials. Aromatic ring substituted dianthracene compounds in the formula (I) present high glass transition temperature and solution efficiency, which can be used as effective blue-light emitting host materials.

Abstract: A synthetic method for preparing organometallic iridium compounds is provided and includes the two steps of (1) synthesizing a di-iridium compound with a halogenated bridge: L2Ir(??X)2IrL2, L; and (2) reacting L2Ir(??X)2IrL2 with a ligand to give the product [C?]N]2Ir (LX). The invention is an improvement over the traditional method for preparing such compounds and has the advantages of shortened reaction time, increased yield, and products of over 99% purity obtained without chromatography.

Abstract: This invention, which belongs to the field of organic synthesis, involves “One-step synthetic method of 2,9-dimethyl-1,7-diphenyl-1,10-phenanthroline”. This method uses O-phenylenediamine and formula III to react under the condition of mixed-shrinking agent, the synthesis can be completed in one step, the stated mixed-shrinking agent is mixture of hydrochloric acid and organic acid. The organic acid serves as phase transfer catalyst and shrinking agent, meanwhile, as buffer reagent, organic acid reduces polymerization of III, and side products as well. The products gained are of high purity and the reaction is mild and easy to control. Since there is no polluting material added and generated, the waste is safe to discharge. In the after treatment of reaction, ketone solvent is used to reduce separation step and product lost, thus improving yield.

Abstract: Disclosed are methods and compositions of assessing one or more statuses of a subject. Also disclosed are methods and compositions of identifying status biomarkers associated with a status of a subject. Also disclosed are sets of one or more status biomarkers. Also disclosed are methods and compositions of producing status biomarker capture probes.

Abstract: This invention, which involves “the preparation method of 8-hydroxyquinoline metallic compound”, is a synthetic method of organic electroluminescent materials. The preparation method of compound Mqnqm? is to add solution prepared by Zengshui solvent and industrial ligand into reaction vessel, stir it at a certain temperature, and then achieve high-purity product, as for the Mqnqm?, M stands for Al, Li, n stands for 1-3, m is 0-2, q is 8-hydroxyquinoline and its derivatives, and q? is ligand different from q. Zengshui solvent is adopted in this invention which can react effectively and thus reducing reaction time and avoiding cumbersome operation and the refining process; this invention also increases total yield and purity, the mother liquor obtained can be recycled, which reduces environment pollution and cost as well.

Abstract: This invention, which involves synthetic method of 5, 5- dimethyl-2, 4-adipaldehyde-0, 0-Boron difluoride, belongs to the field of organic synthesis. Synthetic method of 5, 5-dimethyl-2, 4-adipaldehyde-0, 0-Boron difluoride is to react pinacolone and boron trifluoride diethyl ether at low temperature, and then add aqueous alkaline solution in after treatment to extract product from ether, after that, separate fluid, condense organic phase and final product is obtained. Yield of this method is 2 to 3 times higher than that in literature, and apart from that, mild reaction condition, simple procedures, easy operation, and low cost make it easy for industrial production. The product can be used directly in next step reaction without any special purification.

Abstract: This invention, which belongs to the field of organic electroluminesent materials synthetic technology, involves synthetic method of 10,10?-Dibromo-9,9?-bianthryl. The synthetic method is to use 9,9?-bianthryl as raw material, chlorinated hydrocarbon as solvent, bromide as bromine agent and react. This method not only produces no environmental pollution, but also enjoys high yield, therefore, it is suitable for industrial production.

Abstract: This invention, which involves “the synthetic method of 9, 9?-biantnthracine”, belongs to the field of synthetic technology of organic electroluminesent materials. Synthetic method of 9, 9?-bianthracine is to add anthraquinone as raw material and zinc as reducing agent in glacial acetic acid solution, then batch addition of hydrochloric acid at 70-120°, maintain the temperature unchanged and react, then 9, 9?-bianthracine is achieved. This invention uses one-step method to synthesize 9, 9?-bianthracine, which reduces not only cost but also generation of side products, in addition, the products obtained need no purification and can be directly used to synthesize related similar compounds, therefore, it is very suitable for large-scale industrial production.

Abstract: The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) wherein R1, R2, R3, R4, R5, A, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Abstract: The present invention relates to compounds that are inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3), compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the activation of JNK1, JNK2 and JNK3.

Abstract: The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) wherein R1, R2, R3, R4, R5, A, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Abstract: The present invention is directed to compounds of formula (I), or a pharmaceutically suitable salt or prodrug thereof, which are useful for the selective inhibition of protein tyrosine phosphatase-1B (PTP1B), and are useful for the treatment of disorders caused by overexpressed or altered protein tyrosine phosphatase 1B.

Abstract: The present invention relates to compounds that activate AMP-activated protein kinase (AMPK), including the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, and obesity.

Abstract: The present invention relates to compounds that activate AMP-activated protein kinase (AMPK), including the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, and obesity.

Abstract: The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by ghrelin including anorexia, cancer cachexia, eating disorders, age-related decline in body composition, weight gain, obesity, and diabetes mellitus.